Skip to Content Facebook Feature Image

Lions' 4th-down flops, 3rd-down failures doom them in 16-9 loss in Philadelphia

Sport

Lions' 4th-down flops, 3rd-down failures doom them in 16-9 loss in Philadelphia
Sport

Sport

Lions' 4th-down flops, 3rd-down failures doom them in 16-9 loss in Philadelphia

2025-11-17 14:11 Last Updated At:14:20

PHILADELPHIA (AP) — Jared Goff tried to find the positives for the Lions — such as, a 40-yard touchdown pass to Jameson Williams — that seemingly meant little in a loss when an offense takes an oh-fer on fourth downs.

Goff and the Lions fizzled on fourth.

Try, 0 for 5.

“The fourth downs were the whole thing,” Goff said. “I don't know what we were on third down.”

Don't look at the stat sheet, Jared.

Try, 3 for 13 on third downs.

The Lions failed time after time to get a first down that could have sustained a drive or led to a score against an Eagles defense that turned in a masterpiece. Goff threw for only one touchdown and the failures on fourth doomed the Lions in a 16-9 loss to Philadelphia on Sunday night.

“You'd like to think if we got a fourth down or two, it changes the game,” Goff said.

The Eagles pressured Goff into his worst game of the season, only a week after he threw for 320 yards and three TDs in win at Washington. He was just 14 of 37 passing for 255 yards — with one touchdown and one interception — and his 37.8 completion percentage was the worst of his 10-year career. He entered Sunday completing a league-high 74% of his passes.

Goff was 7 of 25 passing in the second half, the 28% on completions were the lowest in a second half for any quarterback with at least 20-plus attempts since Houston's Brian Hoyer in 2015 (26.1%).

True, the Lions played without tight end Sam LaPorta — placed on the injured list ahead of the game with a back injury — yet even he couldn't have bumped those brutal third- and fourth-down conversations to a competitive number.

The Lions entered averaging 31.4 points per game but scored only one touchdown against the Eagles.

Most of the offensive struggles could be pinned on the Eagles.

Defensive tackles Jalen Carter and Jordan Davis combined for five batted passes. Edge rusher Jaelan Phillips had five tackles, a sack and four QB pressures.

Lions coach Dan Campbell replaced offensive coordinator John Morton as the play-caller last week. Campbell wasn’t ready to say it was a permanent move, although he called plays again against the Eagles.

Campbell wasn’t much of an improvement.

‘I didn’t help those guys," Campbell said. “I hate that.”

The Lions’ notable failure came late in the third quarter while trailing 13-6 after Jared Goff connected with Jahmyr Gibbs for a 42-yard gain that took the ball to the Eagles 22. The Lions went on to get a first-and-goal at the 8, but they turned the ball over on downs.

“We get in the red zone, we have to score a touchdown,” Campbell said. “We can't get away with not scoring there.”

Gibbs finished with 107 yards receiving.

Goff hit Williams for a 40-yard score that tied the game at 6-all late in the second quarter. Williams celebrated by jumping onto the goal post padding and bear-hugging the upright, which earned him a 15-yard unsportsmanlike conduct penalty.

On a blustery night in Philly, those lost yards cost the Lions when Jake Bates was wide right on the 48-yard extra point. Bates did kick a 54-yard field goal with 1:58 left.

“That's not going to be the norm, what happened today,” Campbell said of overall offensive inefficiency. “I don't believe that's going to be here to stay.”

The Lions once failed to convert any of six fourth-down attempts in a 2022 game against Washington, the most failed attempts in any NFL game since at least 1991.

The Lions' offense cost them a win in Philadelphia and —- at least temporarily — a spot in the NFC playoff standings. The Super Bowl champion Eagles stand atop the NFC at 8-2 and the 49ers (7-4) hold the final playoff spot. The Lions host the New York Giants on Sunday.

“I believe this is the best thing for us,” Campbell said. “We're going to learn from this. We're going to get better. We're going to adjust. We'll be hitting our stride when other teams are going to hit their adversity.”

AP NFL: https://apnews.com/hub/nfl

Detroit Lions' Jahmyr Gibbs (0) runs with the ball during the second half of an NFL football game against the Philadelphia Eagles on Sunday, Nov. 16, 2025, in Philadelphia. (AP Photo/Matt Rourke)

Detroit Lions' Jahmyr Gibbs (0) runs with the ball during the second half of an NFL football game against the Philadelphia Eagles on Sunday, Nov. 16, 2025, in Philadelphia. (AP Photo/Matt Rourke)

Detroit Lions quarterback Jared Goff (16) throws during the second half of an NFL football game against the Philadelphia Eagles on Sunday, Nov. 16, 2025, in Philadelphia. (AP Photo/Matt Rourke)

Detroit Lions quarterback Jared Goff (16) throws during the second half of an NFL football game against the Philadelphia Eagles on Sunday, Nov. 16, 2025, in Philadelphia. (AP Photo/Matt Rourke)

Detroit Lions quarterback Jared Goff throws during the second half of an NFL football game against the Philadelphia Eagles on Sunday, Nov. 16, 2025, in Philadelphia. (AP Photo/Matt Slocum)

Detroit Lions quarterback Jared Goff throws during the second half of an NFL football game against the Philadelphia Eagles on Sunday, Nov. 16, 2025, in Philadelphia. (AP Photo/Matt Slocum)

維也納--(BUSINESS WIRE)--十二月 8, 2025--

(美國商業資訊)-- AOP Health持續推進其在骨髓增生性腫瘤(一類特殊且罕見的血液腫瘤)領域的臨床研發計畫。這家專注於罕見疾病治療的公司,於2025年在美國佛羅里達州奧蘭多舉行的第67 屆美國血液學會(American Society of Hematology, ASH)年會上,發布了兩項科學研究成果,將為治療策略帶來新的見解。

本新聞稿包含多媒體資訊。完整新聞稿請見此: https://www.businesswire.com/news/home/20251207103807/zh-HK/

ROP-ET與BESREMI PASS

其中一項臨床研究ROP-ET,探討Ropeginterferon alfa-2b在 原發性血小板增多症 (ET)患者中的使用情況。ET是一種由於體內產生的血小板過多而引發的疾病。此試驗為一項前瞻性、多中心、單組第III期臨床研究,評估Ropeginterferon alfa-2b在無法接受現有細胞減量治療 1 的ET患者中的安全性與療效。

另一項研究為BESREMI-PASS研究,旨在觀察該藥物在 原發性紅血球增多症 (PV)患者日常臨床治療中的效果。PV是一種罕見的血液幹細胞癌症,起源於骨髓造血幹細胞,會導致紅血球、白血球及血小板長期異常增多。

致力於滿足尚未被滿足的醫療需求

上述兩項研究,皆為Ropeginterferon α-2b在協助慢性血癌患者治療方面提供了新的見解。

AOP Health執行長Martin Steinhart總結道: 「AOP Health創立的初衷,正是為了回應罕見疾病領域中尚未被滿足的患者需求。我們對研發的持續投入,正體現了這項承諾,並帶來了新的研究成果。我們很榮幸能在ASH年會上,與全球科學界分享這些發現。」

關於Ropeginterferon alfa-2b

Ropeginterferon alfa-2b為全球首個獲准用於治療真性紅血球增多症(MPN)的干擾素藥物。依據歐盟核准內容,該藥物可作為單一療法,用於治療未出現脾腫大症狀的成人真性紅血球增多症患者。

Ropeginterferon alfa-2b屬於長效單聚乙二醇化脯氨酸干擾素(ATC:L03AB15)。初始治療階段為每兩週給藥一次,待血液學指標穩定後,可延長至每四週給藥一次。藥品採用預充式注射筆設計,供患者進行皮下注射使用。

關於AOP Health

AOP Orphan Pharmaceuticals GmbH (「AOP Health」)為一家跨國企業集團,根植於奧地利,集團總部亦設於此。自1996年成立以來,AOP Health Group持續致力於開發創新治療方案,以回應尚未被滿足的醫療需求,重點聚焦於罕見疾病與重症醫學領域。作為整合式治療方案的國際先驅,AOP Health Group透過子公司、代表處及強大的合作夥伴網路,在全球多地開展業務。秉持「需求、科學、信任」的核心理念,AOP Health Group強調對科研的長期承諾,並重視與醫療專業人士及病友組織的合作,確保關鍵利害關係人的需求能貫穿於公司各項行動之中。(aop-health.com)

1 Kiladjian JJ、Marin FF、Al-Ali HK等。ROP-ET:一項評估Ropeginterferon α-2b在治療選擇有限之原發性血小板增多症患者中有效性與安全性的前瞻性第III期臨床試驗。《血液學年鑑》,2024年3月4日:1–2。

需求、科學、信任。(Needs. Science. Trust.)
AOP Orphan Pharmaceuticals GmbH
AOP Health Group成員

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

請前往 businesswire.com 瀏覽源版本:https://www.businesswire.com/news/home/20251207103807/zh-HK/

CONTACT: 深入咨詢

DI Isolde Fally

Isolde.Fally@aop-health.com

+43-676-500 4048

KEYWORD: AUSTRIA EUROPE UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH CLINICAL TRIALS

SOURCE: AOP Health

Copyright Business Wire 2025.

PUB: 12/08/2025 12:14 AM/DISC: 12/08/2025 12:15 AM

http://www.businesswire.com/news/home/20251207103807/zh

AOP Health執行長Martin Steinhart博士;圖片來源:AOP Health/Studio Koekart

AOP Health執行長Martin Steinhart博士;圖片來源:AOP Health/Studio Koekart

Recommended Articles